Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
24 Janeiro 2024 - 6:30PM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the appointment of Reshema Kemps-Polanco, Executive Vice
President and Chief Commercial Officer, Novartis US, to its Board
of Directors. Ms. Kemps-Polanco has extensive pharmaceutical
industry experience in leading commercial organizations that will
provide a wealth of healthcare business leadership knowledge and
sales and marketing expertise to Charles River’s Board. As a member
of the Board, Ms. Kemps-Polanco will serve on the Compensation and
Strategic Planning and Capital Allocation Committees.
“Reshema Kemp-Polanco’s deep industry experience at two of the
top-10, global pharmaceutical companies and demonstrated ability to
oversee large commercial organizations across multiple therapeutic
areas will greatly benefit Charles River’s Board. Her industry
knowledge will enable Charles River and our Board to gain powerful
insights from a unique, voice-of-customer perspective and help to
support our growth strategy. Reshema is a distinguished leader who
is inspired by reimagining medicine to improve patient access and
health outcomes. She will complement the combined skills and
experience of our current directors, and we are pleased to welcome
Reshema to Charles River’s Board,” said James C. Foster, Chairman,
President and Chief Executive Officer of Charles River.
Ms. Kemps-Polanco has 25 years of pharmaceutical industry
experience and currently serves as Executive Vice President and
Chief Commercial Officer of Novartis US, the U.S. operations of
global biopharmaceutical company, Novartis AG. In this role, she is
responsible for the end-to-end commercialization across four
therapeutic areas, including oncology, immunology, neurology, and
cardiovascular/renal/metabolic conditions. Prior to rejoining
Novartis in 2021, Ms. Kemps-Polanco held several leadership
positions at Johnson & Johnson from 2014 until 2021, most
recently as President, Janssen U.S. Cardiovascular & Metabolism
and Janssen Pharmaceuticals Puerto Rico. In this role, she was
responsible for developing and delivering the business strategy and
driving the growth initiatives for these businesses. Ms.
Kemps-Polanco began her pharmaceutical industry career at Novartis
in sales and held management positions of increasing
responsibility, including leading the U.S. commercial team’s
marketing strategy for its leukemia franchise and as U.S. brand
leader for its osteoporosis therapy.
Through her healthcare leadership roles, Ms. Kemps-Polanco is
committed to decreasing healthcare inequities in screening and
diagnosis and creating equal access to quality healthcare for all
patients. She is a board member of the Healthcare Leadership
Council (HLC), a coalition of chief executives focused on policies
that make quality healthcare accessible to all Americans, a member
of the Healthcare Businesswomen’s Association (HBA) Global Advisory
Board, and the CEO Roundtable on Cancer.
Ms. Kemps-Polanco said, “It’s an opportune time to join Charles
River’s Board of Directors as the pharmaceutical industry navigates
through a myriad of changes from regulatory to the scientific
advancements to treat disease. Charles River is distinctly
positioned to partner with clients to accelerate biomedical
research and therapeutic innovation, and to drive towards the
commercialization of their life-saving therapies in a
cost-effective manner. I look forward to collaborating with the
outstanding team and contributing to the future success and growth
of Charles River.”
Caution Concerning Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “will,”
“may,” “estimate,” “plan,” “outlook,” and “project,” and other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. Forward
looking statements include statements in this press release
regarding the specific contributions of members of Charles River's
Board of Directors. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of
risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated
or implied by the forward-looking statements. A further description
of these risks, uncertainties, and other matters can be found in
the Risk Factors detailed in Charles River's Annual Report on Form
10-K as filed on February 22, 2023, and the Quarterly Report on
Form 10-Q as filed on November 8, 2023, as well as other filings we
make with the Securities and Exchange Commission. Because
forward-looking statements involve risks and uncertainties, actual
results and events may differ materially from results and events
currently expected by Charles River, and Charles River assumes no
obligation and expressly disclaims any duty to update information
contained in this news release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124149888/en/
Investor Contact: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media Contact: Amy Cianciaruso Corporate Vice President, Chief
Communications Officer 781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024